36-month results from phase 1/2a clinical study of RG6501 released
Author(s): Kassi Filkins Key Takeaways RG6501 (OpRegen) cell therapy shows sustained visual acuity and retinal structure improvements in GA patients over 36 months. Extensive coverage of OpRegen therapy leads to…